Navigation Links
BioMarin to Present at the Citi Global Healthcare Conference
Date:2/22/2011

NOVATO, Calif., Feb. 22, 2011 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced that Joshua Grass, Vice President of Corporate and Business Development of BioMarin, will present a company update at the Citi Global Healthcare Conference in New York City on Tuesday, March 1, 2011 at 8:00 a.m. ET.  

Interested parties may access a live audio webcast of the conference call via the investor section of the BioMarin website, www.BMRN.com.  A replay of the call will be archived on the site for one week following the call.

About BioMarinBioMarin develops and commercializes innovative biopharmaceuticals for serious diseases and medical conditions. The company's product portfolio comprises four approved products and multiple clinical and pre-clinical product candidates. Approved products include Naglazyme® (galsulfase) for mucopolysaccharidosis VI (MPS VI), a product wholly developed and commercialized by BioMarin; Aldurazyme® (laronidase) for mucopolysaccharidosis I (MPS I), a product which BioMarin developed through a 50/50 joint venture with Genzyme Corporation; Kuvan® (sapropterin dihydrochloride) Tablets, for phenylketonuria (PKU), developed in partnership with Merck Serono, a division of Merck KGaA of Darmstadt, Germany; and Firdapse™ (amifampridine phosphate), which has been approved by the European Commission for the treatment of Lambert Eaton Myasthenic Syndrome (LEMS). Product candidates include GALNS (N-acetylgalactosamine 6-sulfatase), which is currently in Phase III clinical development for the treatment of MPS IVA, PEG-PAL (PEGylated recombinant phenylalanine ammonia lyase), which is currently in Phase II clinical development for the treatment of PKU, BMN-701, a novel fusion protein of insulin-like growth factor 2 and acid alpha glucosidase (IGF2-GAA), which is currently in Phase I/II clinical development for the treatment of Pompe disease, and BMN-673, a poly ADP-ribose polymerase (PARP) inhibitor, which is currently in Phase I/II clinical development for the treatment of genetically-defined cancers. For additional information, please visit www.BMRN.com. Information on BioMarin's website is not incorporated by reference into this press release.

BioMarin®, Naglazyme® and Kuvan® are registered trademarks of BioMarin Pharmaceutical Inc.

Firdapse™ is a trademark of BioMarin Huxley Ltd.

Aldurazyme® is a registered trademark of BioMarin/Genzyme LLC.Contact:Investors

MediaEugenia Shen

Bob PurcellBioMarin Pharmaceutical Inc.

BioMarin Pharmaceutical Inc.(415) 506-6570

(415) 506-3267
'/>"/>

SOURCE BioMarin Pharmaceutical Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. BioMarin Partner AnGes MG, Inc. Submits BLA to Japanese Ministry of Health
2. BioMarin Announces FDA Approval for Kuvan
3. BioMarin Initiates Phase 1 Clinical Study of PEG-PAL in PKU
4. BioMarin Announces Positive Results From Phase 2A Clinical Study of 6R-BH4 in Sickle Cell Disease
5. BioMarin Initiates Phase 1/2 Clinical Trial for GALNS for Morquio A Syndrome
6. BioMarin Initiates Phase 2 Clinical Study of PEG-PAL in PKU
7. BioMarin Acquires Huxley Pharmaceuticals, Inc.
8. BioMarin to Present at the Oppenheimer Healthcare Conference
9. BioMarin Announces Third Quarter 2009 Financial Results
10. BioMarin to Acquire LEAD Therapeutics
11. BioMarin to Present at the Credit Suisse Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/28/2017)... PHOENIX , March 28, 2017  Today, ... Pharmacy released a new white paper to ... use of latex in healthcare. Specifically, there is substantial confusion ... fact, the FDA has urged manufacturers to drop the term ... labels, because of the challenge to ensure a product is ...
(Date:3/28/2017)... ALBANY, New York , March 28, 2017 /PRNewswire/ ... features a largely consolidated vendor landscape, with the top ... and Agilent Technologies accounting for a significant 49% of ... in a recent report. The vendor landscape is intensely ... large share in the overall market. These factors have ...
(Date:3/28/2017)...  Akcea Therapeutics, a subsidiary of Ionis Pharmaceuticals, Inc. (NASDAQ: ... directors: Christopher Gabrieli , ... as chairman of the board of Akcea Therapeutics. ... Forest Laboratories. Sandford D. Smith , ... "We are excited to announce this expansion to our ...
Breaking Medicine Technology:
(Date:3/29/2017)... ... ... HealthCareMandA.com will host an important webinar — Home Health & Hospice: Buying, ... of the webinar will also be made available following its live presentation. The webinar ... still popular targets for healthcare investors. This highly fragmented sector bounced back in 2016, ...
(Date:3/29/2017)... (PRWEB) , ... March 29, ... ... suburbs and South Hills of Pittsburgh now have easier access to the ... only by Allegheny Health Network (AHN). Orthopaedic surgeons at Forbes Hospital and ...
(Date:3/29/2017)... ... ... has helped over 1.5 million SharePoint users learn the content management system faster and ... for SharePoint was at the farm level. Enterprises using SharePoint Online in Office 365 ... recently released a modified version of the Help System, VisualSP for Site Collections, which ...
(Date:3/28/2017)... ... March 28, 2017 , ... India’s Chigurupati ... to directly address the resolution to globally reduce the harmful use of alcohol ... of FDA and TTB approved ingredients that when infused into alcohol, renders the ...
(Date:3/28/2017)... ... ... The Thyroid Secret is a specialized 9-part documentary series ... recently launched on March 1, and Dr. Wentz discussed varied benefits and aspects ... Wentz is a licensed pharmacist and a foremost thyroid specialist. After being diagnosed ...
Breaking Medicine News(10 mins):